Xenetic Biosciences (XBIO)
(Delayed Data from NSDQ)
$3.57 USD
-0.01 (-0.28%)
Updated Aug 8, 2024 03:31 PM ET
After-Market: $3.67 +0.10 (2.80%) 7:58 PM ET
3-Hold of 5 3
C Value F Growth A Momentum D VGM
Price, Consensus and EPS Surprise
XBIO 3.57 -0.01(-0.28%)
Will XBIO be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for XBIO based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for XBIO
Akebia Therapeutics (AKBA) Reports Q2 Loss, Lags Revenue Estimates
ElectroCore, Inc. (ECOR) Reports Q2 Loss, Tops Revenue Estimates
XBIO: What are Zacks experts saying now?
Zacks Private Portfolio Services
Xenetic Biosciences (XBIO) Reports Q1 Loss, Misses Revenue Estimates
Xenetic Biosciences (XBIO) Reports Q2 Loss, Tops Revenue Estimates
Oncternal Therapeutics (ONCT) Reports Q2 Loss, Lags Revenue Estimates
Other News for XBIO
Xenetic Biosciences Announces Executive Leadership Restructuring
Xenetic Biosciences appoints James Parslow as interim CEO
Xenetic names James Parslow as interim CEO
Xenetic Biosciences, Inc. Announces Executive Leadership Transition
Xenetic Biosciences reports Q1 results